Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Stanford University
Stanford University
OHSU Knight Cancer Institute
Stanford University
Texas Oncology Cancer Center
Case Comprehensive Cancer Center